Interactive Resource
Lewy Body Dementia Treatment Research Pipeline
This tracker presents treatments being studied for dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD), including both treatments targeting underlying disease processes and symptom-directed therapies for specific challenges such as psychosis and cognition.
Select a treatment to see how it works, what the evidence shows so far, and where to find its registered clinical trial.
Treatment Pathways
Managing Symptoms Now
Treatments and strategies currently used to help with symptoms and day-to-day function.
Explore symptom managementTreatments Being Studied
Investigational approaches researchers are testing to slow, prevent, or change the underlying disease.
Currently viewingWhy are DLB and Parkinson's disease dementia shown together?
Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) are closely related disorders involving abnormal accumulation of alpha-synuclein in the brain.
The diagnostic labels differ largely based on when cognitive symptoms develop relative to movement symptoms. In DLB, cognitive symptoms occur before or around the same time as parkinsonism. In PDD, dementia develops after Parkinson's disease has already been established.
Because their underlying biology and treatment research overlap substantially, this tracker presents them together while identifying the population studied in each clinical trial.
What do the phases mean?
Phase 1
Safety & dosingDoes it appear safe enough to keep studying?
The first studies in people. Researchers are primarily looking at safety, dosing, and how the treatment behaves in the body.
Phase 2
Early signalsDoes it affect its target, and is there evidence it might help?
The treatment is tested in more people. Researchers continue studying safety while looking for evidence that it affects its intended target and may provide clinical benefit.
Phase 3
Large-scale testingDoes it meaningfully help patients, and is it sufficiently safe?
Large studies designed to determine whether the treatment is effective and sufficiently safe in the intended patient population. Positive Phase 3 results can support an application for regulatory approval.
A later phase does not mean a treatment is proven to work. Until a treatment has successfully completed clinical testing and received regulatory approval, it remains investigational.
Last pipeline review: September 15, 2026
This is a curated educational resource, not a comprehensive registry. Treatments are selected to illustrate clinically relevant approaches being studied for each disease. Trial status, enrollment, and eligibility should always be confirmed directly through ClinicalTrials.gov.
This pipeline is under active review. Treatment details and trial information are being expanded as individual programs are verified.